These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22687730)

  • 41. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
    Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
    Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Principles and applications of Raman spectroscopy in pharmaceutical drug discovery and development.
    Gala U; Chauhan H
    Expert Opin Drug Discov; 2015 Feb; 10(2):187-206. PubMed ID: 25399993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug discovery and development tomorrow -- changing the mindset.
    Coleman RA
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():1-4. PubMed ID: 19807197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug discovery in the next decade: innovation needed ASAP.
    Bennani YL
    Drug Discov Today; 2011 Sep; 16(17-18):779-92. PubMed ID: 21704185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New methods in pharmaceutical research: combinatorial chemistry and high throughput screening].
    Schirlin D; Galvan M; Le Fur G
    Bull Acad Natl Med; 2007; 191(4-5):727-36; discussion 736-7. PubMed ID: 18225426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3D Printing Pharmaceuticals: Drug Development to Frontline Care.
    Trenfield SJ; Awad A; Goyanes A; Gaisford S; Basit AW
    Trends Pharmacol Sci; 2018 May; 39(5):440-451. PubMed ID: 29534837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Label-free technologies and pharmacology.
    Fang Y
    Pharmacol Res; 2016 Jun; 108():88-89. PubMed ID: 27155057
    [No Abstract]   [Full Text] [Related]  

  • 51. Introduction to the proceedings of the Speed and Safety in Drug Discovery Symposium hosted by the Safer Medicines Trust. Preface.
    Clotworthy M; Archibald K
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():i-iii. PubMed ID: 19953739
    [No Abstract]   [Full Text] [Related]  

  • 52. Combinatorial biosynthesis for drug development.
    Menzella HG; Reeves CD
    Curr Opin Microbiol; 2007 Jun; 10(3):238-45. PubMed ID: 17553731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The economics of drug development: a grim reality and a role for clinical pharmacology.
    Honig P; Lalonde R
    Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
    [No Abstract]   [Full Text] [Related]  

  • 54. Advancing drug discovery: a pharmaceutics perspective.
    Kwong E
    J Pharm Sci; 2015 Mar; 104(3):865-71. PubMed ID: 25482223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of chronobiology to drug discovery.
    Farrow SN; Solari R; Willson TM
    Expert Opin Drug Discov; 2012 Jul; 7(7):535-41. PubMed ID: 22657273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
    [No Abstract]   [Full Text] [Related]  

  • 58. Timely synthetic support for medicinal chemists.
    Potoski J
    Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of drug-induced effect patterns to link structure and side effects of medicines.
    Fliri AF; Loging WT; Thadeio PF; Volkmann RA
    Nat Chem Biol; 2005 Dec; 1(7):389-97. PubMed ID: 16370374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.